AVITA Medical Q2 2024 GAAP EPS $(0.60) Misses $(0.48) Estimate, Sales $15.195M Beat $14.733M Estimate
Portfolio Pulse from Benzinga Newsdesk
AVITA Medical (NASDAQ:RCEL) reported Q2 2024 GAAP EPS of $(0.60), missing the $(0.48) estimate, but sales of $15.195M beat the $14.733M estimate. EPS decreased by 46.34% YoY, while sales increased by 29.29% YoY.
August 08, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AVITA Medical reported Q2 2024 GAAP EPS of $(0.60), missing the $(0.48) estimate, but sales of $15.195M beat the $14.733M estimate. EPS decreased by 46.34% YoY, while sales increased by 29.29% YoY.
The significant miss on EPS is likely to negatively impact the stock price in the short term, despite the positive sales performance. Investors may focus more on the earnings miss and the substantial YoY decrease in EPS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100